IDXX Stock Analysis: Buy, Sell, or Hold?
IDXX - Idexx Laboratories Inc
$670.46
-6.25 (-0.92%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 02, 2026
1d
Get Alerted When IDXX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called IDXX this week
50% bullish • 1 bearish
50% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IDXX shows positive signals but monitor for confirmation. Market pricing in 1.1% decline. Moderate conviction.
💡 BUY OPPORTUNITY: IDXX shows positive signals but monitor for confirmation. Market pricing in 1.1% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$526.16
Based on 7.9% avg growth
INTRINSIC VALUE TODAY
$326.70
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IDXX is currently trading at $670.46, which is considered oversold relative to its 30-day fair value range of $679.62 to $710.42. The stock's valuation (Forward PE: 46.8) is in line with its historical norms (48.5). Remarkably, the market is currently pricing in an annual earnings decline of 1.1% over the next few years. This pessimistic expectation contrasts with the company's recent 21.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, IDXX is showing support break momentum. The price is currently testing key support at $668.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: IDXX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $766.00 (+13.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IDXX is showing support break momentum. The price is currently testing key support at $668.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: IDXX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $766.00 (+13.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$679.62 -
$710.42
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($766.00)
Fair Price Analysis
30-Day Fair Range
$679.62 -
$710.42
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$51.75
(7.7%)
Support & Resistance Levels
Support Level
$668.99
Resistance Level
$719.95
Current Trend
Support Break
Fundamental Context
Forward P/E (Next Year Est.)
46.84
Wall Street Target
$766.00
(+13.2%)
Revenue Growth (YoY)
13.3%
Earnings Growth (YoY)
21.4%
Profit Margin
24.6%
Valuation Discount vs History
-1.1% cheaper
PE vs Historical
46.8 vs 48.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.1%
(market-implied from PE analysis)
1-Year Target
$669.27
(-1%)
2-Year Target
$661.90
(-2%)
3-Year Target
$654.62
(-3%)
3-Yr Target (if PE normalizes)
(PE: 47→49)
$677.79
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 46.8, Growth: 11.7%)
$943.85
(+40%)
Base:
(SPY PE: 22.3, Growth: 11.7%)
$449.34
(-34%)
Bear:
(PE: 19.0, Growth: 11.7%)
$381.94
(-44%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (55x PE), but valuation improves significantly next year (47x PE) as earnings recover.
Trailing PE: 54.63 | Current EPS (TTM): $12.59
Bull Case
$868.07
(+30%)
Analyst growth 14.7%, PE expands to 60.1
Base Case
$789.16
(+18%)
Market implied 14.7%, PE stable at 54.6
Bear Case
$467.66
(-30%)
Severe decline -20.0%, PE contracts to 46.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 46.8 to 48.5
Stabilization Target:
$700.66
(+3.5%)
PE Expansion Potential:
+3.5%
Last updated: January 31, 2026 3:08 PM ET
Data refreshes hourly during market hours. Next update: 4:08 PM
Data refreshes hourly during market hours. Next update: 4:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IDXX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2025-09-05
Byron Donalds
BUY
2025-09-04
M Anne Szostak
SELL
2187 shares
2025-08-22
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$653 | 47 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 57 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$121 | 62 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$263 | 47 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$257 | 58 HOLD |
Advanced IDXX Option Strategies
Professional options setups generated by AI based on today's IDXX price and gamma walls.
